

BIBLIOGRAPHIE : Thérapies Psychédéliques.

Docteur Christian SUEUR, GRECC, version actualisée, décembre 2019.

1. ANDERSON B.T. : Ayahuasca as Antidepressant ? Psychedelics and Styles of Reasoning in Psychiatry, *Anthropology of Consciousness*, 2012, vol. 23, no. 1, 44-59.
2. ANDERSON B.T., LABATE B.C., MEYER M., TUPPER K.W., BARBOSA P.C., GROB C.S. et al. : Statement on ayahuasca, *International Journal of Drug Policy*, 2012, 23, 173–175.
3. ANDERSON T., PETRANKER R., DINH-WILLIAMS L., ROSENBAUM D., WEISSMAN C., HAPKE E., FARBER N. : Microdosing Psychedelics : Personality, Mental Health, and Creativity Differences in Microdosers, version preprint, 6 novembre 2018.
4. ANDERSON T., PETRANKER R., CHRISTOPHER A., ROSENBAUM D., WEISSMAN C., DINH-WILLIAMS L.-A., HUI K., HAPKE E. : Psychedelic microdosing benefits and challenges : an empirical codebook, *Harm Reduction Journal*, 2019.
Doi : 10.1186/s12954-019-0308-4
5. ARGENTO E., TUPPER K.W., SOCIAS M.E. : The tripping point : The potential role of psychedelic-assisted therapy in the response to the opioid crisis, *International Journal of Drug Policy*, 2019, 2 pp. Doi : 10.1016/j.drugpo.2018.11.006
6. BARKER S.A. : N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen : Past, Present, and Future Research to Determine its Role and Function, *Frontiers in Neuroscience*, 2018, 12, Article 536, 1-15.
Doi : 10.3389/fnins.2018.00536
7. BARRETT F.S., ROBBINS H., SMOKE D., BROWN J.L., GRIFFITHS R.R. : Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions, *Frontiers in Psychology*, 2017, 8, 1238.
8. BARRETT F.S., PRELLER K.H., KAELEN M. : Psychedelics and music : neuroscience and therapeutic implications, *International Review of Psychiatry*, 2018, 1-13.
Doi : 10.1080/09540261.2018.1484342
9. BAUMEISTER D., BARNES G., GIAROLI G., TRACY D. : Classical hallucinogens as antidepressants ? A review of pharmacodynamics and putative clinical roles, *Therapeutic Advances in Psychopharmacology*, 2014, 4, 156-69.
10. BEGOLA M.J., SCHILLERSTROM J.E. : Hallucinogens and Their Therapeutic Use : A Literature Review, *Journal of Psychiatric Practice*, 2019, 25, (5), 334–346.
Doi : 10.1097/PRA.0000000000000409
11. BIANCARDI V. : La recherche sur les microdoses de substances psychédéliques. James Fadiman, Sophie Forbes et les « micro-doses », *Revue Chimères*, 2017, 1, 91, 139-148.
<https://www.cairn.info/revue-chimeres-2017-1-page-139.htm>
12. BIANCARDI V. : Le microdosage de substances psychédéliques : bref historique et nouveaux axes de recherche, *Revue Circé*, 2019, 11, 1-24.
<http://www.revue-circe.uvsq.fr/biancardi-microdosage-de-substances-psychedeliques/>
13. CALDERON S.N., HUNT J., KLEIN M. : A regulatory perspective on the evaluation of hallucinogen drugs for human use, *Neuropharmacology*, 2018, 142, 135-142.
Doi : 10.1016/j.neuropharm.2017.11.028
14. CAMERON A., LUKE D., WALDSTEIN A., SESSA B., KING D. : Breaking Convention. Essays on Psychedelic Consciousness, North Atlantic Books, Berkeley, CA, 2013, 2014.

15. CARHART-HARRIS R.L., LEECH R., WILLIAMS T., ERRITZOE D., ABBASI N., BARGIOTAS T. et al. : Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin, *British Journal of Psychiatry*, 2012, 200, 238-244.
doi: 10.1192/bjp.bp.111.103309
16. CARHART-HARRIS R.L., GOODWIN G.M. : The Therapeutic Potential of Psychedelic Drugs : Past, Present and future, *Neuropsychopharmacology*, 2017, 42, 2105-2113.
Doi : 10.1038/npp.2017.84
17. CARHART-HARRIS R.L., ROSEMAN L., HAIJEN E. et al. : Psychedelics and the essential importance of context, *Journal of Psychopharmacology*, 2018, 32, (7), 725-731.
18. CHAMBON O. : La médecine psychédélique, Ed. Les Arènes, Saint-Amand-Montrond, 2009, 396 p.
19. COLEMAN R. : Psychedelic Psychotherapy. A User Friendly Guide to Psychedelic Drug Assisted Psychotherapy, Transform Press, Berkeley, CA, USA, 2018.
20. Dos SANTOS R.G., OSORIOS F.L., CRIPPA J.A.S., RIBA J., ZUARDI A.W., HALLAK J.E.C. : Antidepressive, anxiolytic, and anti-addictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years, *Therapeutic Advances Psychopharmacology*, 2016, 6, 3, 193- 213.
21. Dos SANTOS R.G., BOUSO J.C., HALLAK J.E.C. : Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer, *BMC Psychiatry*, 2019, 19, 321, 1-4.
Doi : 10.1186/s12888-019-2288-z
22. DYCK E. : Psychedelic Psychiatry. LSD, from clinic to campus, The John Hopkins University Press, Baltimore, 2008.
23. FADIMAN J. : Microdose research without approvals, control groups, double-blinds, staff or funding, note non publiée, 2010.
24. FADIMAN J. : The Psychedelic Explorer's Guide, in « Psychedelic Medicine », R.L. Miller Ed., Rochester, Vermont, Park Street Press, 2011.
25. FRECSKA E. : Therapeutic Guidelines : Dangers and Contra-indications in Therapeutic Applications of Hallucinogens (Chapter 4), in Winkelman Michael & Thomas B. Roberts (editors) « *Psychedelic Medicine: New Evidence for Hallucinogenic Substances as Treatments* », Praeger, Westport, CT./Greenwood, London, 2007.
26. FREDERKING W., Intoxicant drugs (mescaline and lysergic acid diethylamide) in psychotherapy, *Journal of Nervous and Mental Disease*, 1955, 121, 262-266.
27. GARCIA-ROMEU A., KERSGAARD B., ADDY P.H. : Clinical applications of hallucinogens: A review, *Experimental and Clinical Psychopharmacology*, 2016, 24, (4), 229-268.
Doi: 10.1037/pha0000084
28. GARDNER J., CARTER A., O'BRIEN K., SEEAR K. : Psychedelic-assisted therapies. The past, and the need to move forward responsibly, *International Journal of Drug Policy*, 2019.
29. GASSER P., HOLSTEIN D., MICHEL Y., DOBLIN R., YAZAR-KLOSINSKI B., PASSIE T. et al. : Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases, *Journal of Nervous and Mental Disease*, 2014, 202, 513-520.
30. GEORGE J.R., MICHAELS T.J., SEVELIUS J., WILLIAMS M.T. : The psychedelic renaissance and the limitations of a White-dominant medical framework : a call for indigenous and ethnic minority inclusion, *Journal of Psychedelic Studies*, 2019, 12 p.
Doi : 10.1556/2054.2019.015
31. GIRN M., CHRISTOFF K. : Expanding the Scientific Study of Self-Experience with Psychedelics, *Journal of Consciousness Studies*, 2018, 25, (11-12), 131-154.

32. GREER G.R., TOLBERT R.A. : A method of conducting therapeutic sessions with MDMA, *Journal of Psychoactive Drugs*, 1998, 30, (4), 371-379.
33. GREER G.R., TOLBERT R.A. : The therapeutic use of MDMA, in « *Ecstasy : The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA* », S.J. Peroutka ed., Holland, Kluwer, 1990
34. GREER G.R., TOLBERT R.A. : Subjective reports of the effects of MDMA in a clinical setting, *Journal of Psychoactive Drugs*, 1986, 18, (4), 319-327.
35. GRINSPOON L., BAKALAR J.B. : Psychedelic Drugs Reconsidered, Basic Books, New York/Lindesmith Center, New York, 1979/1997.
36. GRINSPOON L., BAKALAR J.B. : Therapeutic uses, in « *Psychedelic Drugs Reconsidered* », The Lindesmith Center, New York, 1997, 192-237.
37. GRINSPOON L., BAKALAR J.B. : Adverse Effects and their Treatment (Chapter 5), in « *Psychedelic Drugs Reconsidered* », The Lindesmith Center, New York, 1997.
38. GROB C. : Psychiatric research with hallucinogens : What have we learned ? *The Yearbook for Etnomedicine and the Study of Consciousness*, 1994, Issue 3.
39. GROB C.S., DANFORTH A.L., CHOPRA G.S., HAGERTY M., MCKAY C.R., HALBERSTADT A.L., et al. : Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer, *Archives of General Psychiatry*, 2011, 68, 71-78.
40. GROF S. : LSD psychotherapy, Santa Cruz, CA, Multidisciplinary Association for Psychedelic Studies, 2001.
41. GROF S. : The principle of LSD psychotherapy, in « *LSD Psychotherapy* », Multidisciplinary Association for Psychedelic Studies, Sarasota, FL, 2001. (now Santa Cruz, CA.)
42. GROF S. : Personality of the Therapist or Guide, pages 87-101, in « *LSD Psychotherapy* », Multidisciplinary Association for Psychedelic Studies, Sarasota, FL, 2001. (now Santa Cruz, CA.)
43. GROF S. : The Ultimate Journey : Consciousness and the Mystery of Death, Multidisciplinary Association for Psychedelic Studies, Santa Cruz, CA, 2006.
44. HARRIES-REES K. : Taking a medical trip, Chemistry World, 2007, 68-71.
45. HENTZEN A., PASSIE T. : The Pharmacology of LSD : A Critical Review, Beckley Foundation and Oxford University Press, 2010.
46. HOFMANN A. : LSD, mon enfant terrible (LSD, mein Sorgenkind, LSD, My Problem Child), Ernst Klett Ed., Stuttgart, 1979, McGraw-Hill Book Company, 1980 (trad. Anglaise), Gris Banal Ed., 1989 (trad. Française), Editions du Lézard, 1997.
47. IBRAHIM L., DIAZ GRANADOS, N., FRANCO-CHAVES J. et al. : Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study, *Neuropsychopharmacology*, 2012, 37, 1526-1533.
48. INGOLD F.R., SUEUR C., KAPLAN C.D. : Contribution à une exploration des propriétés thérapeutiques du cannabis, *Annales médico-psychologiques. Revue psychiatrique*, 2015, 173, (5), 453-459.
<http://dx.doi.org/10.1016/j.amp.2015.04.001>
49. JAMES E., ROBERTSHAW T.L., WESTWELL A.D. : Emerging from the dark side : new therapeutic applications of scheduled psychoactive substances, *Future Medicinal Chemistry*, February 2019, 4 p.
Doi : 10.4155/fmc-2018-0447
50. JANIGER O. : The use of hallucinogenic agents in psychiatry, *Californian Clinician*, 1960, 56, 222-224, 251-259

51. JANOS B.K., PETER K. : Research ethics aspects of experimentation with LSD on human subjects : a historical and ethical review, *Medecine, Health Care and Philosophy*, 2018, 11 p.
Doi : 10.1007/s11019-018-9871-9
52. JOHNSON M.W., RICHARDS W.A., GRIFFITHS R.R. : Human Hallucinogen Research : Guidelines for Safety, *Journal of Psychopharmacology*, 2008, 22, (6), 603-620.
Doi : 10.1177/0269881108093587
53. JOHNSON M.W., GRIFFITHS R.R. : Potential therapeutic effects of psilocybin, *Neurotherapeutics*, 2017, 14, 734–740.
doi: 10.1007/s13311-017-0542-y
54. JOHNSON M.W. : Psychiatry might need some psychedelic therapy, *International Review of Psychiatry*, Institute of Psychiatry and Johns Hopkins University, 2018, 30, 4, 285-290.
<https://doi.org/10.1080/09540261.2018.1509544>
55. JOHNSON M.W., HENDRICKS P.S., BARRETT F.S., GRIFFITHS R.R. : Classic psychedelics : an integrative review of epidemiology, therapeutics, mystical experience and brain network function, *Pharmacology & Therapeutics*, 2019.
<https://doi.org/10.1016/j.pharmther.2018.11.010>
56. KAFKALIDIS A. : Application thérapeutique de la Diethylamide de l'acide lysergique (Delysid ou LSD 25) sur les psychonévroses, *Annales Médico-Psychologiques*, 1963, 121, (2), 191-200.
57. KELLY J.R., BAKER A., BABIKER M., BURKE L., BRENNAN C., O'KEANE V. : The psychedelic renaissance : the next trip for psychiatry ?, *Irish Journal of Psychological Medicine*, 2019, 1-5.
Doi : 10.1017/ipm.2019.39
58. KOTLER M. : MDMA-assisted Psychotherapy in Twelve People with War and Terrorism-related Post-Traumatic Stress disorders (PTSD), MAPS MDMA/PTSD Israel, *Tel Aviv University*, 2006 April 10.
59. KREBS T.S., JOHANSEN P. O. : Psychedelics and mental health: a population study, *PLoS One*, 2013, 8, e63972
60. KURLAND A.A., GROF S., PAHNKE W.N., GOODMAN L.E. : Psychedelic drug assisted psychotherapy in patients with terminal cancer, *Journal of Thanatology*, 1972, 2, 644–691.
61. KVAM T.-M., STEWART L.H., ANDREASSEN O.A. : Psychedelic drugs in the treatment of anxiety, depression and addiction, *Tidsskriftet, Den Norske Legeforening*, November 2018.
Doi : 10.4045/tidsskr.17.1110
<https://www.researchgate.net/publication/332136512>
62. LABATE B.C., CAVNAR C. (Eds.) : The Therapeutic Use of Ayahuasca, Springer-Verlag, Berlin, Heidelberg, 2014.
63. LANGLITZ N. : Neuropsychadelia : The Revival of Hallucinogen Research Since the Decade of the Brain, University of California Press, Berkeley and Los Angeles, California, 2013.
64. LANGLITZ N. : Psychedelics can't be tested using conventional clinical trials, *Aeon*.
<https://aeon.co/ideas/psychedelics-can-t-be-tested-using-conventional-trials>
65. LEVY-WILLARD A. : Rencontre avec le Professeur Baastians, in « *Les visions d'un rescapé ou le Syndrome d'Auschwitz* », KA-TZETNIK 135633, Hachette, 1990, 157-164.
66. LETHEBY C. : The Varieties of Psychedelic Epistemology, in « *Psychedelicacies : more food for thought from Breaking Convention* », N. Wyrd, D. Luke, A. Tollar, C. Adams and D. King (eds.), Strange Attractor Press, 2019.
67. LOVE S. : The Ethics of Taking the Drugs you Study. Should psychedelic scientists trip on the drugs they research ?, *VICE.com*, May 14, 2019.

https://www.vice.com/en_us/article/qv7jkx/the-ethics-of-taking-the-drugs-you-study

68. MASSON N.L., KUYPERS K.P.C. : Mental Health of a self-selected sample of psychedelic users and self-medication practices with psychedelics, *Journal of Psychedelic Studies*, 2018, 2, (1), 45-52.
Doi : 10.1556/2054.2018.006
69. MICHAELS T.I., PURDON J., COLLINS A., WILLIAMS M.T. : Inclusion of people of color in psychedelic-assisted psychotherapy : a review of the literature, *BMC Psychiatry*, 2018, 18, 245, 14 pp.
<https://doi.org/10.1186/s12888-018-1824-6>
70. MILLER R.L. : Psychedelic Medicine. The Healing Powers of LSD, MDMA, Psilocybin, and Ayahuasca, with texts of Dennis McKenna, Stanislav Grof, James Fadiman, Rick Doblin, Julie Holland and others, Park Street Press, Rochester, Vermont, USA, Toronto, Canada, 2017.
71. MITHOEFER M.C., GROB C.S., BREWERTON T.D. : Novel psychopharmacological therapies for psychiatric disorders : psilocybin and MDMA, *Lancet Psychiatry*, 2016, 3, 481–488.
doi: 10.1016/S2215-0366(15)00576-3
72. MITHOEFER M.C., WAGNER M.Y., MITHOEFER A.T., JEROME L., DOBLIN R. : The Safety and Efficacy of {+/-} 3,4-methylenedioxymethamphetamine-assisted Psychotherapy in Subjects with Chronic, Treatment-resistant Posttraumatic Stress Disorder : The First Randomized Controlled Pilot Study, *Psychopharmacology*, 2011, 25, (4), 439-452.
73. MITHOEFER M. : MDMA-assisted Psychotherapy for the Treatment of Post-traumatic Stress Disorder, in Michael Winkelman & Thomas B. Roberts (editors) « *Psychedelic Medicine : New Evidence for Hallucinogenic Substances as Treatments* », Vol. 1, Praeger, Westport, CT/Greenwood, London, 2007.
74. MOGAR R.E., ALDRICH R.W. : The Use of Psychedelic Agents with Autistic Schizophrenic Children, *Psychedelic Review*, 1969, Vol. 10, 5-13.
75. MORRIS K. : Research on Psychedelics Moves into the Mainstream, *The Lancet*, 2008, 371, 1491-1492.
76. MORRIS K. : Hallucinogen Research Inspired Neurotheology, *The Lancet Neurology*, 2006, 5, (9), p 732.
77. NICHOLS D.E., JOHNSON M.W., NICHOLS C.D. : Psychedelics as medicines : an emerging new paradigm, *Clinical Pharmacology & Therapeutics*, 2017, 101, 209–219.
doi: 10.1002/cpt.557
78. NIDA : MDMA/Ecstasy Research : Advances, Challenges, Future Directions. A Scientific Conference, July 19-20, 2001, *National Institute of Health, National Institute on Drug Abuse*.
<https://archives.drugabuse.gov/meetings/MDMA/MDMAAbs2.html>
79. ONA G., TRONCOSO S. : Long-lasting analgesic effect of the psychedelic drug change : A case report, *Journal of Psychedelic Studies*, 2019, 3, (1), 7–13.
Doi: 10.1556/2054.2019.001
80. ORAM M. : Efficacy and Enlightenment : LSD Psychotherapy and the Drug Amendments of 1962, *Journal of History of Medicine and Allied Sciences*, 2014, 69, 2, 221-250.
Doi : 10.1093/jhmas/jrs050
81. ORAM M. : Prohibited or regulated ? LSD psychotherapy and the United States Food and Drug Administration, *History of Psychiatry*, 2016, 27, (3), 290-306.
Doi : 10.1177/0957154X16648822

82. ORAM M. : *The Trials of Psychedelic Therapy. LSD Psychotherapy in America*, John Hopkins University Press, 2018.
83. OSSEBAARD H.C. : A Dissertation On the Constructive (Therapeutic and Religious) Use of Psychedelics : A Request for Support, *Revue du MAPS*, 2001, vol XI, n°2, 12-13.
84. PASSIE T. : *Psycholytic and Psychedelic Therapy Research 1931-1995 : A Complete International Bibliography*, Laurentis Publishers, Hannover, Germany, Lists 687 studies, 1997.
85. PASSIE T. : *The Science of Microdosing Psychedelics*, Falmouth, Psychedelic Press, 2018.
86. PERRINE D. : *The Chemistry of Mind-altering Drugs : History, Pharmacology, and Cultural Context*, American Chemical Society, Washington, DC, 1996.
87. PHELPS J. : developing Guidelines and Competencies for the trainiong of Psychedelic Therapists, *Journal of Humanistic Psychology*, 2017, 38 p.
Doi : 10.1177/0022167817711304
88. PHIFER B. : A review of the research and theological implications of the use of psychedelic drugs with terminal cancer patients, *Journal of Drug Issues*, 1997, 7, (3), 287-292.
89. POLLAN M. : *How To Change Your Mind. The New Science of Psychedelics*, Penguin Books, UK/USA/Canada/Ireland/Australia..., 2018.
90. POSTRÁNECKÁ Z., VEJMOLA C. and TYLŠ F. : Psychedelic therapy in the Czech Republic: A theoretical concept or a realistic goal?, *Journal of Psychedelic Studies*, 2019, 3, (1), 19-31.
Doi : 10.1556/2054.2019.003
91. REICHE S., HERMLE L., GUTWINSKI S., JUNGABERLE H., GASSER P. MAJIC T. : Serotonergic hallucinogens in treatment of anxiety and depression in patients suffering from a life-threatening disease : A systematic review, *Progress in Neuropsychopharmacology and Biological Psychiatry*, 2018, 81, 1-10.
Doi : 10.1016/j.pnpbp.2017.09.012
92. RHEAD J.C. : The Use of Psychedelic Drugs in the Treatment of Severely Disturbed Children : A Review, *Journal of Psychedelic Drugs*, 1977, 9, (2), 95-101.
93. RICHARDS W.A., RHEAD J.C., DiLEO F.B., YENSEN R., KURLAND A.A. : The peak experience variable in DPT-assisted psychotherapy with cancer patients, *Journal of Psychoactive Drugs*, 1977, 9, 1-10.
doi: 10.1080/02791072.1977.10472020
94. ROSENBAUM D., WEISSMAN C., HAPKE E., HUI K., PETRANKER R., DINH-WILLIAMS L.-A. et al. : Microdosing psychedelic substances : demographics, psychiatric comorbidities, and comorbid substance use, *in preparation*.
95. RUCKER J.J.H., JELEN L.A., FLYNN S., FROWDE K.D., YOUNG A.H. : Psychedelics in the treatment of unipolar mood disorders : a systematic review, *Journal of Psychopharmacology*, 2016, 1-10.
Doi : 10.1177/0269881116679368
96. RUCKER J.J.H., ILIFF J., NUTT D.J. : Psychiatry & the psychedelic drugs. Past, present & future, *Neuropharmacology*, 2018, 142, 200e218.
Doi : 10.1016/j.neuropharm.2017.12.040
97. SCHENBERG E.E. : Psychedelic-Assisted Psychotherapy : A Paradigm Shift in Psychiatric Research and Development, *Frontiers in Pharmacology*, 2018, 11 pp.
Doi : 10.3389/fphar.2018.00733
98. SCHULTES E., HOFMANN A., RATSCHE C. : *Plants of Gods*, Rochester, Vermont Healing Arts Press, 1998.

99. SCOTT G., CARHART-HARRIS R.L. : Psychedelics as a treatment for disorders of consciousness, *Neuroscience of Consciousness*, 2019, 5, (1), niz003.
Doi : 10.1093/nc/niz003
100. SESSA B. : Can psychedelics have a role in psychiatry once again ?, *British Journal of Psychiatry*, 2005, 186, 457-458
Doi : 10.1192/bjp.186.6.457
101. SESSA B. : Are psychedelic drug treatments seeing a comeback in psychiatry, *Progress in Neurology and Psychiatry*, 2008, 12, (8), 5-10.
Doi : 10.1002/pnp.94
102. SESSA B. : Is it time to revisit the role of psychedelic drug in enhancing human creativity ?, *Journal of Psychopharmacology*, 2008.
103. SESSA B. : Shaping the renaissance of psychedelic research, *Lancet*, 2012, 380, (9838), 200-201.
Doi : 10.1016/S0140-6736(12)60600-X
104. SESSA B. : Why Psychiatry needs psychedelics and psychedelics need psychiatry, *Journal of Psychoactive Drugs*, 2014, 46, (1), 57-62.
Doi : 10.1080/02791072.2014.877322
105. SESSA B. : Can 3,4-methylenedioxymethamphetamine therapy, be used to treat alcohol use disorder ?, *Journal of Psychedelic Studies*, 2017, 1, (1), 1-9.
Doi : 10.1556/2054.01.2016.003
106. SESSA B. : The History of Psychedelics in Medicine, 2016, in « *Handbuch Psychoaktive Substanzen* », Springer-Verlag GmbH, Deutschland, 1-26.
107. SESSA B. : Why Psychiatry Needs 3,4-methylenedioxymethamphetamine : A Child Psychiatrist 's Perspective, *Neurotherapeutics*, 2017, 14, (3), 741-749.
Doi : 10.1007/s13311-017-0531-1
108. SESSA B. : The Psychedelic Renaissance, Reassessing the Role of Psychedelic Drugs, in « *21st Century Psychiatry and Society* », London, UK, Muswell Hill Press, 2017.
109. SESSA B., HIGBED L., NUTT D. : A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy, *Frontiers in Psychiatry*, 2019, 7 p.
Doi : 10.3389/fpsyg.2019.00138
110. SHAGASS C., BITTLE R.M. : Therapeutic Effect of LSD : A Follow-up Study, *Journal of Nervous and Mental Disease*, 1967, 144, (6), 471-478.
111. SHANON B. : Antipodes of the Mind : Charting the Phenomenology of the Ayahuasca Experience, Oxford, UK, Oxford University Press, 2002.
112. SHANON B. : Moments of Insight, Healing, and Transformation : A Cognitive Phenomenological Analysis, Chapter 4, in « *The Therapeutic Use of Ayahuasca* », B.C. Labate and C. Cavnar, Springer Berlin Heidelberg, 2014, 59-132.
113. SHULGIN Al., SHULGIN An. : PIHKAL, A Chemical Love Story, Transform Press, Berkeley, CA, 1991, 1995.
114. SHULGIN Al., SHULGIN An. : TIHKAL, The Continuation, Transform Press, Berkeley, CA, 1997.
115. SHULGIN Al., SHULGIN An. : A New Vocabulary, in « *Entheogens and the Future of Religion* », Council on Spiritual Practices, 1997.
116. SLOSHOWER J. : Integrating Psychedelic Medicines and Psychiatry : Theory and Methods of a Model Clinic, Chapter 7, in « *Plant Medicines, Healing and Psychedelic Science : Cultural Perspectives* », Beatriz Caiuby Labate & Clancy Cavnar (Eds), 2018, Springer International Publishing AG.
Doi : 10.1007/978-3-319-76720-8_7

<https://www.youtube.com/watch?v=9uvFSCxcl3I&feature=youtu.be>

117. STANSBURY K.A. : The Influence of Psychedelic Induced Ego-Dissolution on Self-Compassion, Thesis, School of Social Work California State University, Long Beach, *B.A., 2011, California State University, Dominguez Hills*, May 2019.
118. STRASSMAN R.J. : Human hallucinogenic drug research : regulatory, clinical, and scientific issues, *NIDA Research Monography*, 1994, 146, 92-123.
119. SUEUR C. et al. Les substances hallucinogènes et leurs usages thérapeutiques. Revue de la littérature, partie 1, 1999, et partie 2, 2000, *Revue Toxibase*
http://www.cirddalsace.fr/docs/revue_toxibase/pdf/dossier_halluci.pdf
http://www.cirddalsace.fr/docs/revue_toxibase/pdf/dossier_halluc2.pdf
120. SUEUR C. : La recherche sur les capacités thérapeutiques des « substances hallucinogènes », *Chimères*, 2017, 91, 121-138.
121. SUEUR C. : Etat des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21^e siècle, *Psychotropes*, 2017, 24, (3-4), 125-163.
122. SWANSON L.R. : Unifying Theories of Psychedelic Drug Effects, *Frontiers in Pharmacology*, 2018, 23 pp.
Doi : 10.3389/fphar.2018.00172
123. TUPPER K.W., WOOD E., YENSEN R., JOHNSON M.W. : Psychedelic medicine : a re-emerging therapeutic paradigm, *Canadian Medical Association Journal*, 2015, 187, 1054-1059
Doi : 10.1503/cmaj.141124
124. UTHAUG M.V., LANCELOTTA R., van OORSOUW K., KUYPERS K.P.C., MASON N., RAK J., ŠULAKOVA A., JUROK R., M. MARYSKA M., KUCHAR M., T. PALENICEK T., RIBA J., RAMAEKERS J.G. : A single inhalation of vapor from dried toad secretion containing 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms, *Psychopharmacology*, 2019.
<https://doi.org/10.1007/s00213-019-05236-w>
125. VARLEY J. : Psychedelic-assisted therapy for anxiety and depression in the face of death : A critical review with an anthropological lens, *Journal of Psychedelic Studies*, 2019, 3, (1), 14-18
Doi : 10.1556/2054.2019.005
126. VEROUST V. : Des cannabinoïdes à la psilocybine : des psychotropes thérapeutiques ?, in « 24^e rencontres du RESPAAD – GRECC », 21 juin 2019, Paris.
127. VOLLENWEIDER F.X., KOMETER M. : The neurobiology of psychedelic drugs: implications for the treatment of mood disorders, *Nature Reviews Neuroscience*, 2010, 11, 642-651.
128. WHELAN A., JOHNSON M.I. : Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain : a potential role ?, *Pain Management*, 2018.
Doi : 10.2217/pmt-2017-0068
129. WILDBERGER J.I., JOHN C.N., HALLOCK R.M. : Perceptions of the medicinal value of hallucinogenic drugs among college students, *Journal of Psychedelic Studies*, 2017, 1(2), pp. 50-54
Doi: 10.1556/2054.01.2017.008
130. WINKELMAN M., ROBERTS T. (Eds) : Psychedelic Medicine : New Evidence for Hallucinogenic Substances as Treatments, Westport, CT, Praeger, 2007.
131. WINKELMAN M. : Psychedelics as medicines for substance abuse rehabilitation : Evaluating treatments with LSD, peyote, ibogaine and ayahuasca, *Current Drug Abuse Reviews*, 2014, 7, (2), 101-116.

Doi : [10.2174/1874473708666150107120011](https://doi.org/10.2174/1874473708666150107120011)

132. WINKELMAN M., SESSA B. Editors : Advances in Psychedelic Medicine. State-of-the-Art. Therapeutic Applications, Praeger, Santa Barbara California, Denver Colorado, 2019.
133. WOLFSON P.E. : Psychedelic Experiential Pharmacology : Pioneering Clinical Explorations with Salvador Roquet. An Interview with Richard Yensen, *International Journal of Transpersonal Studies*, 2014, 33, (2), 160-174.
134. YENSEN R. : Thirty Years of Psychedelic research : The Spring Grove Experiment and its Sequels, *European College of Consciousness (ECBS) International Congress, Worlds of Consciousness in Göttingen*, Germany, 24-27 September 1992.
135. YENSEN R. : Perspectives on LSD & Psychotherapy : Search for a New Paradigm, Drug Policy Foundation Conference, Washington DC, November 20-21, 1993.
136. YENSEN R. : From Shamans and Mystics to Scientists and Psychotherapists : Interdisciplinary Perspectives on the Interaction of Psychedelics Drugs and Human Consciousness, in *Yearbook in Cross-Cultural Medicine and Psychotherapy* (Verlag), entitled « *The Constructive Potential of Psychedelics : Cross-Cultural Perspective* », 1995.
137. YENSEN R., DRYER D.A. : The Consciousness Research of Stanislas Grof : A Cosmic portal Beyond Individuality, 1998, 23 p.
138. YENSEN R. : Pilgrimage to the Light ? on the Threshold of a Dream : Sacred Plants, Passionate Dedication to Ideals, and Healing, Chapter 8, in Project « *Documentary « Remembering Salvador » the Life and Work of Salvador Roquet, MD* », 2015.
<https://www.researchgate.net/publication/282132139>
139. YENSEN R. : Psychedelic Experiential Pharmacology : Pioneering Clinical Explorations with Salvador Roquet (How I Came to All of This: Ketamine, Admixtures and Adjuvants, Don Juan and Carlos Castaneda Too), An Interview with Richard Yensen, in Project « *Documentary « Remembering Salvador » the Life and Work of Salvador Roquet, MD* », 2015, *International Journal of Transpersonal Studies*, 2015, 33, (2), 160-174.

Addictions et thérapies psychédéliques :

1. ABUZZAHAB F.S., ANDERSON B. J. : A review of LSD treatment in alcoholism. *International Pharmacopsychiatry*, 1971, 6 (4), 223–235.
Doi : 10.1159/000468273
2. ARGENTO E., BRASCHEL M., WALSH Z., EUGENIA SOCIAS M., SHANNON K. : The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women, *Journal of Psychopharmacology*, 2018,
Doi : 10.1177/0269881118798610
3. BASTIAANS E. : Life after ibogaine : An exploratory study of the long-term effects of ibogaine treatment on drug addicts, 2004.
www.ibogaine.desk.nl/ibogaine_udl_bastiaans.pdf
4. BOGENSCHUTZ M. P., JOHNSON M. W. : Classic hallucinogens in the treatment of addictions, *Progress in NeuroPsychopharmacology & Biological Psychiatry*, 2016, 64, 250–258.
Doi : 10.1016/j.pnpbp.2015.03.002
5. BOGENSCHUTZ M.P., FORCEHIMES A.A., POMMY J.A., WILCOX C.E., BARBOSA P., STRASSMAN R.J. : Psilocybin-assisted treatment for alcohol dependence : A proof-of-concept study, *Journal of Psychopharmacology*, 2015, 29, (3), 289–299.
Doi : 10.1177/0269881114565144
6. BRIGHT S., WILLIAMS M., CALDICOTT D. : Should addiction researchers be interested in psychedelic science ? Editorial, *Drug and Alcohol Review*, 2017.
Doi : 10.1111/dar.12544
7. BROWN T. K. : Ibogaine in the treatment of substance dependence, *Current Drug Abuse Reviews*, 2013, 6, 3–16.
Doi : 10.2174/15672050113109990001
8. DANFORTH A.L., GROB C.S., STRUBLE C., FEDUCCIA A.A., WALKER N., JEROME L., YAZAR-KLOSINSKI B., EMERSON A. : Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults : a randomized, double-blind, placebo-controlled pilot study, *Psychopharmacology*, 2018,
<https://doi.org/10.1007/s00213-018-5010-9>
9. DENYS A. : Importance d'une approche globale dans le traitement des addictions. Iboga et Ayahuasca, des perspectives intéressantes, in « *Chamanisme et thérapeutiques. Mythe ou réalité* », Jacques Fleurentin (ed), Metz, IEE-SFE, 10 juin 2004, Société française d'Ethnopharmacologie.
10. DENYS A. : Alliance des médecines occidentales et traditionnelles dans le traitement des addictions, Mémoire de Maîtrise Sciences Sanitaires et Sociales, Mention Santé Publique, Faculté de Médecine / Université Henri Poincaré Nancy 1, 2004-2005.
11. DENYS A. : des plantes médicinales au service d'une action thérapeutique dans la prise en charge de l'addiction, *Ethnopharmacologia*, 2013, 50, 69-78.
12. DORSEN C., PALAMAR J., SHEDLIN M.G. : Ceremonial « Plant Medicine » use and its relationship to recreational drug use : an exploratory study, *Addiction Research and Theory*, 2018, 8 p.
Doi : 10.1080/16066359.2018.1455187
13. DOS SANTOS R.G., OSORIO F. L., CRIPPA J.A.S., RIBA J., ZUARDI A. W., HALLAK J.E.C. : Antidepressive, anxiolytic, and anti-addictive effects of ayahuasca,

- psilocybin and lysergic acid diethylamide (LSD) : A systematic review of clinical trials published in the last 25 years, *Therapeutic Advances in Psychopharmacology*, 2016, 6, (3), 193–213.
Doi : 10.1177/2045125316638008
14. EISCHENS P., ATHERTON L.W. : Psychedelic therapy as a complementary treatment approach for alcohol use disorders, *Journal of Psychedelic Studies*, 2018, 2, (1), pp. 36–44
Doi : 10.1556/2054.2018.005
15. GARCIA-ROMEU A., DAVIS A.K., EROWID F., EROWID E., GRIFFITHS R.R., JOHNSON M.W. : Cessation and reduction in alcohol consumption and misuse after psychedelic use, *Journal of Psychopharmacology*, 2019, 1-14.
Doi : 10.1177/0269881119845793
16. GLUE P., CAPE G., TUNNICLIFF D., LOCKHART M., LAM F., HUNG N., HUNG C.T., HARLAND S., DEVANE J., CROCKETT R.S., HOWES J., DARPO B., ZHOU M., WIS H., FRIEDHOFF L. : Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients, *Clinical Pharmacology in Drug Development*, 2016, 5, (6), 460–468.
Doi : 10.1002/cpdd.254
17. GRIFFITHS R., GROB C. : Hallucinogens as Medicine, *Scientific American*, 2010, 76-79.
18. JOHNSON M.W, GARCIA-ROMEU A., JOHNSON P.S., GRIFFITHS R.R. : An online survey of tobacco smoking cessation associated with naturalistic psychedelic use, *Journal of Psychopharmacology*, 2017, 31, (7), 841–850.
19. JOHNSON M.W., HENDRICKS P.S. , BARRETT F.S., GRIFFITHS R.R. : Classic psychedelics : An integrative review of epidemiology, therapeutics, mystical experience, and brain network function, *Pharmacology & Therapeutics*, 2019. <https://doi.org/10.1016/j.pharmthera.2018.11.010>
20. KARILA L., REYNAUD M., AUBIN H. J., ROLLAND B., GUARDIA D., COTTENCIN O., BENYAMINA A. : Pharmacological treatments for cocaine dependence: Is there something new ?, *Current Pharmaceutical Design*, 2011, 17, 1359–1368.
Doi : 10.2174/138161211796150873
21. KREBS T.S., JOHANSEN P.-Ø. : Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials, *Journal of Psychopharmacology*, 2012, 26, (7), 994–1002.
Doi : 10.1177/0269881112439253
22. KRUPITSKY E.M., GRINENKO A.Y., BERKALIEV T.N. et al. : The combination of psychedelic and aversive approaches in alcoholism treatment : The affective contra-attribution method, *Alcoholism Treatment Quarterly*, 1992, 9, 99-105.
23. KRUPITSKY E. : Underlying psychological mechanisms of ketamine psychedelic therapy (KPT) in the treatment of alcohol dependency : preliminary report, *Bulletin of the MAPS*, 1995, 6, (1), 2 p.
24. KRUPITSKY E. : Ketamine study at Yale : an update, *Bulletin of the MAPS*, 1996, 7, (1), 1.
25. KRUPITSKY E.D., GRINENKO A.Y. : Ketamine psychedelic therapy : a review of the results of ten years of research, *Journal of Psychoactive Drugs*, 1997, 8, (2), 165-182.
26. KRUPITSKY E.D., GRINENKO A.Y. : Ten years study of ketamine psychedelic therapy of alcohol dependence, *The Heffter Review of Psychedelic Research*, 1998, 8, 1, 56-61.
27. KRUPITSKY E.D. BURAKOV A., GRINENKO A. Y. : Correlation Between Ketamine Psychotherapy (KPT) Induced Psychological Changes and Alcoholism Treatment

- Outcome, *Bulletin of the MAPS*, 1999, 9, (1), 39-40.
28. KRUPITSKY E.D. BURAKOVA., ROMANOVA T., VOSTRIKOV V., GRINENKO A.Y. : The syndrome of anhedonia in recently detoxified heroin addicts assessment and treatment, *Bulletin of the MAPS*, 1999, 9, (1), 40-41.
 29. KRUPITSKY E.D. : Ketamine psychedelic therapy : two reports, *Bulletin of the MAPS*, 1999, 9, (1), 39-41.
 30. KRUPITSKY E.M., BURAKOV A., DUNAEVSKYI. V. et al. : Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence, *Journal of Psychoactive Drugs*, 2007, 39, (1), 13-19.
 31. KRUPITSKY E.M., BURAKOV A., ROMANOVA T. : Ketamine psychotherapy for heroin addiction : immediate effects and two-year follow-up, *Journal of Substance Abuse Treatment*, 2002, 23, 273-283.
 32. KRUPITSKY E.M., GRINENKO A.Y. : Ketamine psychedelic therapy (KPT) : a review of the results of ten years of research, *Journal of Psychoactive Drugs*, 1997, 29, (2), 165-183.
 33. KVAM T.-M., STEWART L.H., ANDREASSEN O.A. : Psychedelic drugs in the treatment of anxiety, depression and addiction, *Tidsskriftet, Den Norske Legeforening*, 2018.
Doi : 10.4045/tidsskr.17.1110
 34. LIESTER M.B. : A Review of Lysergic Acid Diethylamide (LSD) in the Treatment of Addictions : Historical Perspectives and Future Prospects, *Current Drug Abuse Reviews*, 2014, 7, 146-156.
 35. MCLEAN J.R., MacDONALD D.C., OGDEN F., WILBY E. : LSD-25 and mescaline as therapeutic adjuvants, in Abramson H.A. (Ed.) : « *Use of LSD in Psychotherapy and Alcoholism* », Bobbs-Merrill, Indianapolis, 1967, 407-426.
 36. NOORANI T., GARCIA-ROMEU A., SWIFT T.C., GRIFFITHS R.R., JOHNSON M.W. : Psychedelic therapy for smoking cessation : Qualitative analysis of participant accounts, *Journal of Psychopharmacology*, 2018, 1-14.
Doi : 10.1177/0269881118780612
 37. O'REILLY P., FUNK A. : LSD in chronic alcoholism, *Canadian Psychiatric Association Journal*, 1964, 9, 258-261.
Doi : 10.1177/070674376400900311
 38. OSMOND H., CHEEK F., ALBAHARY R., SARRET M. : Some Problems in the use of LSD 25 in the Treatment of alcoholism, in Abramson H.A. (Ed.) : « *Use of LSD in Psychotherapy and Alcoholism* », Bobbs-Merrill, Indianapolis, 1967, 434-453.
 39. SAVAGE C., McCABE O.L. : Residential Psychedelic (LSD) Therapy for the Narcotic Addict, *Archives of General Psychiatry*, 1973, 28, 808-814.
 40. SOSKIN R.A. : The Use of LSD in Time-Limited Psychotherapy, *Journal of Nervous and Mental Disease*, 1973, 157, (6), 410-419.
 41. THOMAS G., LUCAS P., CAPLER R.N., TUPPER K.W., MARTIN G. : Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada, *Current Drug Abuse Review*, 2013, 6 (1).
http://www.maps.org/research-archive/ayahuasca/Thomas_et_al_CDAR.pdf
 42. WINKELMAN M.J., ROBERTS T.B. : Psychedelic Medicine : New Evidence for Hallucinogenic Substances As Treatments (Vol 1 & 2), Westport, CT, Praeger/Greenwood Publishers, 2007.
 43. WINKELMAN M.J. : Shamanism : A biopsychosocial paradigm of consciousness and healing (2nd ed.), Santa Barbara, CA: ABC-CLIO, 2010.
 44. WINKELMAN M.J. : Psychedelics as medicines for substance abuse rehabilitation : Evaluating treatments with LSD, peyote, ibogaine and ayahuasca, *Current Drug*

Abuse Reviews, 2014, 7, 101-116.

45. YASGHUR B.S. : Ketamine Promising in Cocaine Addiction, *Medscape Medical News*, 2019
https://www.medscape.com/viewarticle/915260_print
46. ZINBERG N. : Drugs : Set and Setting, New Haven, Yale University Press, 1984.